strongbridge biopharma plc sbbpo company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile strongbridge biopharma plc sbbpo related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse sbbpo on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description strongbridge biopharma plc incorporated on may   is a global commercialstage biopharmaceutical company the company is focused on the development and commercialization of therapies for a range of diseases the companys commercial product keveyis dichlorphenamide is indicated for the treatment of hyperkalemic hypokalemic and related variants of primary periodic paralysis a neuromuscular disorder the united states food and drug administration fda has granted orphan drug designation for keveyisthe company has a clinicalstage pipeline of therapies for endocrine diseases the companys lead compounds include cor levoketoconazole and cor veldoreotide the companys product candidate cor is a cortisol synthesis inhibitor the company is studying cor for the treatment of endogenous cushings syndrome the company is conducting a phase iii trial of cor for patients with endogenous cushings syndrome the companys product candidate cor is a somatostatin analog ssa the company is investigating cor for the treatment of acromegaly with additional applications in cushings syndrome and neuroendocrine tumors cor is being optimized for sustained release and subcutaneous delivery both cor and cor have received orphan designation from the fda and the european medicines agency ema » full overview of sbbpo company address strongbridge biopharma plc  northbrook dr ste trevose   pa    p f  company web links home page officers  directors name compensation john johnson  matthew pauls  a davis  stephen long  robert lutz  » more officers  directors strongbridge biopharma plc news briefstrongbridge biopharma secures  mln financing from crg jul   briefstrongbridge biopharma plc posts q loss per share  may   briefstrongbridge biopharma files for mixed shelf offering of up to  mln apr   briefstrongbridge biopharma plc phase  sonics study more than  pct enrolled mar   » more sbbpo news related topics stocksstock screenerhealthcarepharmaceuticals veldoreotide  strongbridge biopharma veldoreotideyou are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseok   strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharma plc  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » strongbridge biopharma plcstrongbridge biopharma plc  by strongbridge biopharma plc a biopharmaceutical company through its subsidiary cortendo ab publ develops acquires and commercializes product candidates that target rare diseases the company’s lead product candidate cor levoketoconazole is a cortisol inhibitor that is in the phase  trial for the treatment of endogenous cushing’s syndrome it also has two product candidates cor and cor in phase  clinical development to treat acromegaly in addition it is developing bp a preclinical product candidate for the treatment of diabetes the company was formerly known as cortendo plc and changed its name to strongbridge biopharma plc in september  strongbridge biopharma plc was founded in  and is based in trevose pennsylvania strongbridge biopharma plc strongbridge biopharma plc a biopharmaceutical company through its subsidiary cortendo ab publ develops acquires and commercializes product candidates that target rare diseases the company’s lead product candidate cor levoketoconazole is a cortisol inhibitor that is in the phase  trial for the treatment of endogenous cushing’s syndrome it also has two product candidates cor and cor in phase  clinical development to treat acromegaly in addition it is developing bp a preclinical product candidate for the treatment of diabetes the company was formerly known as cortendo plc and changed its name to strongbridge biopharma plc in september  strongbridge biopharma plc was founded in  and is based in trevose pennsylvania twitter facebook google linkedin strongbridge biopharma plcpstrongbridge biopharma plc a biopharmaceutical company through its subsidiary cortendo ab publ develops acquires and commercializes product candidates that target rare diseases the company’s lead product candidate cor levoketoconazole is a cortisol inhibitor that is in the phase  trial for the treatment of endogenous cushing’s syndrome it also has two product candidates cor and cor in phase  clinical development to treat acromegaly in addition it is developing bp a preclinical product candidate for the treatment of diabetes the company was formerly known as cortendo plc and changed its name to strongbridge biopharma plc in september  strongbridge biopharma plc was founded in  and is based in trevose pennsylvaniap paunited statesphone  sbbp developing drugs for rare diseases documents roadshow main categoryhealthcare categoriesdrugs contact httpwwwstrongbridgebiocom  address northbrook drive suite  trevose pennsylvania  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member strongbridge biopharma’s history  milestones company historyfounded in  in sweden as cortendo ab our original focus was on regulating cortisol secretion in patients with diabetes in the course of reinventing refocusing and reinvigorating the company strongbridge biopharma has reached a series of pivotal business and clinical milestones  an important year for strongbridge in december  strongbridge biopharma acquired the us rights to keveyis® dichlorphenamide this acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare and orphan diseases that are underdiagnosed and undertreated key milestones recent clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development for keveyis important safety information please see full prescribing information pdfyou are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseoklearn more about our investigational therapiesrecorlev™ levoketoconazole and veldoreotide   strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharma cushing’s syndrome  acromegaly acromegalybased on recent publications we estimate that  patients in the us and eu combined are currently diagnosed with acromegaly acromegaly is typically caused by benign pituitary tumors that oversecrete growth hormone which leads to elevated levels of igf producing the clinical signs and symptoms that characterize acromegaly these effects may manifest slowly over the course of a decade or more clinical development in acromegaly veldoreotide is a novel investigational product under development by strongbridge for use in treating acromegaly the safety and efficacy of veldoreotide for treatment of acromegaly have not been established references companysponsored analysis and published research including jakob dal “incidence and late prognosis of acromegaly in denmark preliminary data”  lugo g pena l cordido f clinical manifestations and diagnosis of acromegaly int j endocrinol  httpdxdoiorg accessed december   ayuk j sheppard mc does acromegaly enhance mortality rev endocr metab disord  bates as van’t hoff w jones jm clayton rn an audit of outcome of treatment in acromegaly q j med  dekkers om biermasz nr pereria am romijn ja vandenbroucke jp mortality in acromegaly a metaanalysis j clin endocrinol metab  manjila s wu oc khan fr et al pharmacological management of acromegaly a current perspective neurosurg focus  octe mayo clinic staff diseases and conditions acromegaly symptoms mayo foundation for medical education and research website httpwwwmayoclinicorgdiseasesconditionsacromegalybasicssymptomscon accessed december   you are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseokrare disease resourcesonline information and supportreferences companysponsored analysis and published research including jakob dal “incidence and late prognosis of acromegaly in denmark preliminary data”  lugo g pena l cordido f clinical manifestations and diagnosis of acromegaly int j endocrinol  httpdxdoiorg accessed december   ayuk j sheppard mc does acromegaly enhance mortality rev endocr metab disord  bates as van’t hoff w jones jm clayton rn an audit of outcome of treatment in acromegaly q j med  dekkers om biermasz nr pereria am romijn ja vandenbroucke jp mortality in acromegaly a metaanalysis j clin endocrinol metab  manjila s wu oc khan fr et al pharmacological management of acromegaly a current perspective neurosurg focus  octe mayo clinic staff diseases and conditions acromegaly symptoms mayo foundation for medical education and research website httpwwwmayoclinicorgdiseasesconditionsacromegalybasicssymptomscon accessed december     strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance rare disease portfolio  strongbridge biopharma rare disease portfoliostrongbridge is dedicated to bridging treatment gaps in rare diseases like primary periodic paralysis endogenous cushing’s syndrome and acromegaly our franchisebased model allows us to leverage company expertise—in both the clinical and commercial development realms—to provide a range of therapeuticallyaligned products rare disease assets in addition to our lead drug candidates which have begun clinical development and have been granted orphan drug designation from both the fda and ema we have acquired the us rights to keveyis® dichlorphenamide the first and only fdaapproved treatment for hyperkalemic hypokalemic and related variants of primary periodic paralysis keveyis has also been granted orphan drug designation by the fda a growing portfolio of products  indicationtarget diseasepreclinicalphase iphase iiphase iiimarketedkeveyis®dichlorphenamideprimary periodic paralysis fda approved fda orphan drug designationmarketedrecorlev™levoketoconazoleendogenous cushings syndrome fda and ema orphan drug designationphase iiiveldoreotideveldoreotideacromegaly fda and ema orphan drug designationphase ii keveyis® the first and only fdaapproved treatment for hyperkalemic hypokalemic and related variants of primary periodic paralysis keveyis is proven to reduce attacks of primary periodic paralysis read more about keveyis® recorlev levoketoconazole cortisol synthesis inhibitor for endogenous cushing’s syndrome recorlev levoketoconazole is being evaluated in sonics a phase  trial for patients with endogenous cushing’s syndrome originally developed as a potential treatment for patients with diabetes strongbridge pivoted the focus of clinical development for recorlev levoketoconazole to treatment of endogenous cushing’s syndrome in  read more about recorlev levoketoconazole veldoreotide novel somatostatin analogue for acromegaly veldoreotide is a somatostatin analogue ssa with a differential somatostatin receptor subtype binding profile  the safety and efficacy of recorlev levoketoconazole and veldoreotide have not been established keveyis® indication keveyis® is indicated for the treatment of primary hyperkalemic periodic paralysis primary hypokalemic periodic paralysis and related variants important safety information in clinical studies the most common side effects of keveyis were a numbness or tingling difficulty thinking and paying attention changes in taste and confusion these are not all of the possible side effects that you may experience with keveyis talk to your doctor if you have any symptoms that bother you or do not go away keveyis is not for everyone do not take keveyis if you are on a highdose aspirin regimen are allergic to sulfabased drugs have liver kidney or certain lung conditions are pregnant planning to become pregnant or nursing are under  years old taking keveyis may cause a drop in the amount of potassium an electrolyte in your body which can lead to heart problems ask your doctor if you need to eat foods that contain high amounts of potassium while taking keveyis your body may produce too much acid or may not be able to remove enough acid from body fluids while taking keveyis your doctor will run tests on a regular basis to check for signs of acid buildup and may reduce your dose or stop your treatment with keveyis keveyis may also increase the risk of falls especially in elderly patients and patients taking high doses of keveyis use caution when driving operating machinery or performing any other hazardous activities while taking keveyis as this medication may cause drowsiness you are encouraged to report side effects to strongbridge biopharma at  or to the fda at fda or visit wwwfdagovmedwatch for more information go to wwwkeveyiscom for additional keveyis important safety information please see full prescribing information pdf reference keveyis® package insert trevose pa strongbridge biopharma  you are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseokreference keveyis® package insert trevose pa strongbridge biopharma    strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharma rare focusrare commitmentrare passionjoin our teamlearn more about becoming part of a team that is driven by passion and focused on resultsacquisition of keveyis® dichlorphenamidelearn more about this fdaapproved product for patients with an ultrarare diseasephase  cushing’s syndrome trialsonics is enrolling patients with endogenous cushing’s syndrome focus on bridging treatment gaps at strongbridge biopharma our focus on rare diseases has resulted in a portfolio of innovative treatments for rare endocrine conditions as well as the acquisition of the us rights to keveyis committed to positive results at strongbridge biopharma we are committed to delivering better results for patients healthcare providers employees and investors learn more about the strongbridge difference passion for compassion the strongbridge team is passionate about making a positive difference in the lives of patients with rare diseases it’s why we’re here meet the strongbridge leadership team   strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge leadership team leadership teampassion for compassion our leadership and management teams are focused on meeting patients’ needs in rare medical conditions and committed to delivering results for all strongbridge stakeholders matthew paulspresident and ceoboard of directors“our mission is to bridge treatment gaps for patients with rare diseases”matt has more than  years of leadership experience in the pharmaceutical industry with an emphasis on specialty pharma and rare disease he brings extensive general management and commercial leadership experience to strongbridge biopharma including us and global product launches and brand management business development clinical development and technical operations before joining strongbridge matt was chief commercial officer at insmed a publicly traded biopharmaceutical company prior to that he served as senior vice president head of global commercial operations at shire pharmaceuticals and also held senior positions at bristolmyers squibb in brand management and payer marketing and at johnson  johnson in various us and global commercial roles matt was previously a member of the board of directors at mast therapeutics inc and currently serves on the board of directors of strongbridge biopharma savara pharmaceuticals and is a volunteer board member of the pennington school in pennington new jersey and the boys  girls clubs of philadelphia matt holds an mba and bs degree from central michigan university and earned his jd from michigan state university college of law fredric cohen mdchief medical officerlorem ipsumfred joined strongbridge in  and has held roles of increasing responsibility including senior vice president global research and development and vice president clinical research and development fred is an endocrinologist by training with more than  years of drug and business development experience most recently focused in development and commercialization of rare disease and specialty products prior to joining strongbridge fred provided strategic and operational counsel to life science companies actively supporting their development and licensing functions prior to that he served as executive director clinical pipeline at aptalis pharma where he was responsible for innovation strategy as well as building and advancing the company’s specialty pharma pipeline he has also held research and development positions with johnson  johnson and eli lilly  company fred holds an md from pennsylvania state university college of medicine and an ab in biology from franklin and marshall college a brian davischief financial officer“our goal is to do right by all stakeholders not just shareholders”brian has more than  years of experience in management and financial activities with life sciences companies including equity and debt financings restructuring activities strategic transactions and negotiations involving partnering licensing drug discovery and clinical development most recently he served as senior vice president and cfo at tengion earlier in his career he held a series of positions of increasing responsibility during his  years at neose technologies including senior vice president and cfo brian holds an mba from the wharton school at the university of pennsylvania and a bs in accounting from trenton state college stephen longchief legal officer“we’re here to meet the challenges posed by rare diseases”steve’s year career has been focused on navigating the legal complexities faced by life sciences companies including publicly traded development and commercialstage firms corporate governance transaction structuring and negotiation complex litigation compliance initiatives intellectual property management regulatory and clinical matters and public company representation have all fallen under his purview steve has served as an attorney at reed smith llp and spent  years at cr bard where he rose through the organization to become vice president general counsel and secretary he has also served as assistant general counsel at warnerlambert company steve received his jd from albany law school of union university and a bs from the school of industrial and labor relations at cornell university robert lutzchief business officer“we’re in the business of improving care for patients with rare diseases”rob leads the business development efforts and commercial strategy implementation at strongbridge biopharma he brings  years of experience in finance business development and product management to the team prior to joining strongbridge rob worked at shire for  years in a number of diverse roles with increasing global responsibility he also draws upon substantial experience in the financial and energy sectors rob holds an mba from the kellogg school of management and a ba in economics and computer science from amherst college dave bonnellsenior vice president sales and marketinglorum ipsumdave has more than  years of commercial experience within the biopharmaceutical industry before joining strongbridge he served as vice president rare disease and gi specialty sales at shire pharmaceuticals where he directed multiple highlyspecialized sales teams focused on two rare diseases hypoparathyroidism and short bowel syndrome prior dave served as vice president neuroscience sales at shire where he successfully led the adhd sales organization in addition he served in a variety of sales and marketing leadership positions at astrazeneca dave holds a bs in business administration from central michigan universityjames r englund cpa cmavice president corporate controllerlorem ipsumjim has nearly  years of experience in finance and accounting fields with nearly  years in pharmaceutical industry finance for commercialstage companies prior to joining strongbridge jim served as corporate controller at auxilium pharmaceuticals inc for nearly  years jim has also held positions at ims health corporation and aventis behring corporation he began his career with positions at coopers and lybrand and sundstrand corporation now united technologies before focusing on the pharmaceutical sector jim holds a bs in accounting from rockford university and is a certified public accountant ann hutchinsonvice president portfolio optimizationlorem ipsumann brings a unique blend of marketing financial and business development skills applied to the commercialization of life science innovations for more than  years she has been passionate about bringing vision clarity and momentum to biopharmaceutical companies’ pipeline opportunities before joining strongbridge in  she led the commercial launch of daytrana® methylphenidate at shire the first transdermal medication for the treatment of adhd for the next eight years she led a consultancy which focused on expanding her clients’ capacity to pursue new product opportunities providing strategic marketing insights during design of clinical development programs and enhancing launch plans to accelerate product trial and adoption prior ann spent  years with merck gaining experience with business development market research sales and marketing – including a tenyear emphasis on marketing planning for products in phase i through launch ann received her mba in finance from columbia university and a bs in chemical engineering from penn statestephen j moloney mdvice president global medical affairslorem ipsumstephen brings more than  years of global medical affairs experience he joined strongbridge from ptc therapeutics where he served as vice president medical affairs and was responsible for prelaunch planning and launch efforts for genetic neuromuscular orphan disease product development in the americas region prior stephen led several key product launches in genetic and rare diseases serving as executive medical director at aegerion senior medical director at shire human genetic therapies european medical director at aspreva pharmaceuticals and roles of increasing responsibility at glaxosmithkline and astrazeneca stephen holds an md from bristol university and completed a residency at newcastle university both in the united kingdomsteven l schoenfeld mdvice president clinical research and developmentlorem ipsumsteve’s clinical development career includes over  years of multinational drug development experience prior to joining strongbridge he served as senior vice president clinical development at viking therapeutics where he was responsible for small molecules development for endocrine disorders leading ind submissions and authoring key data presentations and publications prior to viking therapeutics steve served as vice president clinical affairs at armagen therapeutics and calcimedica inc and in several positions of increasing clinical responsibility under various divisions of pfizer steve holds an md from new york medical college and received his bs in biomedical sciences at the sophie davis school of biomedical education of the city college of new yorksusan thorntonvice president regulatory affairslorem ipsumsusan has nearly  years of senior regulatory affairs experience with specialty pharmaceutical companies before joining strongbridge susan was vice president regulatory affairs at antares pharma where she served as a key contributor for the submission approval and launch of the company’s first commercialized product prior she held roles of increasing responsibility at aptalis pharma inc barrier therapeutics and teva pharmaceuticals usa her development and postapproval product experience includes gastroenterology rheumatology dermatology urology biologics generics and devices susan holds an ms degree in quality assurance and regulatory affairs from temple university school of pharmacy and a bs in chemistry from rider university peter j valentinssonsenior vice president global technical operationslorem ipsumpete has  years of technical operations experience in bringing new pharmaceutical products to the global marketplace with specific experience in formulation development process development scaleup technology transfer and validation for both sterile and nonsterile products he has held positions of increasing seniority at both large pharmaceutical and biotechnology companies including serving most recently as vice president global pharmaceutical sciences at nps pharmaceuticals inc which was acquired by shire previously he served as senior director pharmaceutical sciences quality and also headed one of the product development groups at scheringplough research institute pete holds an ms and a bs degree in chemical engineering from the new jersey institute of technology scott wilhoitsenior vice president global market access and patient serviceslorem ipsumscott brings nearly  years of industry experience most of which has been focused within market and patient access in the rare disease category he most recently served as vice president market and patient access at marathon pharmaceuticals where he designed and developed the access strategy including a comprehensive patient services and distribution model previously scott served as vice president market access and health services at ptc therapeutics leading the prelaunch market access strategy and tactical planning efforts for the company’s duchenne muscular dystrophy treatment in addition he served as vice president pricing access and patient services at nps pharmaceuticals inc scott has also served in a variety of positions with increasing responsibility at clarus therapeutics auxilium pharmaceuticals biovail corporation and johnson  johnson scott served as a field artillery officer in the us army and holds a bs in criminology from missouri western state universitypreviousnextleadership teammatthew pauls president and ceoboard of directorsfredric cohen md chief medical officera brian davis chief financial officerstephen long chief legal officerrobert lutz chief business officersenior management teamdave bonnell senior vice president sales and marketingjames r englund cpa cma vice president corporate controllerann hutchinson vice president portfolio optimizationstephen j moloney md vice president global medical affairssteven l schoenfeld md vice president clinical research and developmentsusan thornton vice president regulatory affairspeter j valentinsson senior vice president global technical operationsscott wilhoit senior vice president global market access and patient servicesyou are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseokstrongbridge financial informationwe are building a strong financial foundation to enable clinical innovation   strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharmaceutical careers  job openings careersstrongbridge is an agile organization that focuses on developing and commercializing treatments for patients with rare diseases our team is always on the lookout for focused committed and passionate people if that describes you check out our open positions current positions although we have no open positions right now we’re always on the lookout for people who can make us stronger send your resume to hrstrongbridgebiocom so that we can consider you when we have a position that matches your profile take a look at our current career opportunities below if one of these opportunities seems like a good fit send your résumé to hrstrongbridgebiocom be sure to include the job title in the subject line of your email   business development executive director business development you are leaving this siteyou are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty websitecloseokkeveyis® dichlorphenamidelearn more about this fdaapproved product for patients with an ultrarare disease   strongbridge biopharma plc strongbridge biopharma™ is a trademark of strongbridge biopharma plc keveyis® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone   infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharma plc added to the russell ® index  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street strongbridge biopharma plc added to the russell ® index globenewswire jun    am edt dublin ireland and trevose pa june   globe newswire  strongbridge biopharma plc nasdaqsbbp a global commercialstage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs today announced that it has been added to the broadmarket russell ® index which includes the smallcap russell ® index at the conclusion of the russell indexes annual reconstitution effective after the us market opens on june   annual russell indexes reconstitution captures the  largest us stocks as of the end of may ranking them by total market capitalization membership in the us allcap russell ® index allows for automatic inclusion in the largecap russell ® index or smallcap russell ® index ftse russell determines membership for its russell indexes primarily by objective marketcapitalization rankings and style attributes russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies approximately  trillion in assets are benchmarked against russells us indexes russell indexes are part of ftse russell a leading global index provider for more information on the russell ® index and the russell indexes reconstitution visit the russell reconstitution section on the ftse russell website about   strongbridge biopharma  strongbridge biopharma is a global commercialstage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs strongbridges first commercial product is keveyis® dichlorphenamide the first and only fdaapproved treatment for hyperkalemic hypokalemic and related variants of primary periodic paralysis keveyis has orphan drug exclusivity status in the us through august   in addition to establishing this neuromuscular disease franchise the company has a clinicalstage pipeline of therapies for rare endocrine diseases strongbridges lead compounds include recorlev ™ levoketoconazole a cortisol synthesis inhibitor currently being studied for the treatment of endogenous cushings syndrome and veldoreotide a nextgeneration somatostatin analog being investigated for the treatment of acromegaly with potential additional applications in cushings syndrome and neuroendocrine tumors both recorlev and veldoreotide have received orphan designation from the us food and drug administration and the european medicines agency for more information visit  wwwstrongbridgebiocom contactscorporate and media relationselixir health public relationslindsay rocco lroccoelixirhealthprcominvestor relationsusthe trout groupmarcy nanus mnanustroutgroupcomeuropefirst housemitra hagen negård    strongbridgebiofirsthousenousa northbrook drivesuite trevose pa tel  fax   if you liked this article you might like perrigo taro show perils of failure to branch in branded drugs the latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of highermargin branded products william mcconnell may    pm edt take a look at these stocks poised to trade higher these  stocks under  look poised to potentially trade higher thestreet staff feb    pm est these  stocks under  could explode higher heres a technical look at how to trade several under  stocks that could trigger big breakout trades soon roberto pedone feb    pm est these  stocks under  could explode higher soon heres a technical look at how to trade several under stocks triggering breakout trades roberto pedone jan    pm est trending how amazon billionaire jeff bezos gained vast riches and a tech giant someday worth  trillion jim cramer nails starbucks big decline warns again of downside to  heres why snaps stock could be in for another big plunge on monday teslas model  arrives on friday  heres everything you need to know about this overhyped ride ipod nano shuffle are dead here are  other discontinued apple products advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers strongbridge biopharma plc secures  million financing from crg  strongbridge biopharma plc – ir site skip to main navigation investors back strongbridge biopharma plc secures  million financing from crg  financing comprised of  million credit facility and  million equity investment  simultaneously retiring existing debt  funds received at close provide sufficient cash under current operating plan to extend cash runway to positive cash flow dublin ireland and trevose pa july   globe newswire   strongbridge biopharma plc nasdaqsbbp a global commercialstage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs today announced that it has entered into a  million senior credit facility with crg lp “crg” a healthcarefocused investment firm to retire its existing debt facility and provide additional capital for the company  strongbridge initially borrowed  million under the term loan agreement and has the option to borrow an additional  million based upon the achievement of certain revenue milestones on or prior to june   concurrent with this first tranche crg purchased  million of the company’s ordinary shares at a price of  per share  “we are pleased to have both the support and confidence of crg a premier partner known for its strategic investments to support the growth of healthcare companies” said matthew pauls chief executive officer of strongbridge “we executed this financing to transform the financial outlook of the company by fully funding our operating plan until we attain positive cash flow the funds received at closing provide sufficient resources for us to build upon the early uptake and demand that we are seeing for keveyis® dichlorphenamide and to fund recorlev™ levoketoconazole through potential regulatory approval and launch” pauls added “strongbridge is in a unique position to address major areas of unmet need in rare disease said luke düster managing director at crg “crg looks forward to working with strongbridge as they continue to build their global business and advance their product pipeline our due diligence has confirmed our belief that strongbridges portfolio has great potential and that access to funds from this financing will help build value for the company” the term loan agreement has a sixyear term with three years of interestonly payments the interestonly period may be extended to six years based upon the achievement of certain milestones during the first three years of the loan term as a condition to the new credit facility the company issued warrants with a sevenyear term to crg to purchase  of the company’s ordinary shares at an exercise price of  per share after the retirement of existing debt and payment of expenses associated with the financing strongbridge intends to use the remainder of the upfront proceeds from the credit facility and equity investment for general corporate purposes and working capital additional details regarding this financing will be available in the company’s current report on form k to be filed with the securities and exchange commission armentum partners served as financial advisor to strongbridge for this transaction  about strongbridge biopharmastrongbridge biopharma is a global commercialstage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs strongbridges first commercial product is keveyis® dichlorphenamide the first and only fdaapproved treatment for hyperkalemic hypokalemic and related variants of primary periodic paralysis keveyis has orphan drug exclusivity status in the us through august   in addition to establishing this neuromuscular disease franchise the company has a clinicalstage pipeline of therapies for rare endocrine diseases strongbridges lead compounds include recorlev™ levoketoconazole a cortisol synthesis inhibitor currently being studied for the treatment of endogenous cushings syndrome and veldoreotide a nextgeneration somatostatin analog being investigated for the treatment of acromegaly with potential additional applications in cushings syndrome and neuroendocrine tumors both recorlev and veldoreotide have received orphan designation from the us food and drug administration and the european medicines agency for more information visit wwwstrongbridgebiocom about crgcrg is a premier healthcarefocused investment firm with more than  billion of assets under management across more than  portfolio companies the firm seeks to commit between  to  million in each investment across the healthcare spectrum including medical devices biopharmaceuticals tools  diagnostics services and information technology crg provides growth capital in the form of longterm debt and equity to support innovative commercialstage healthcare companies that address large unmet medical needs the firm partners with public and private companies to provide flexible financing solutions and worldclass support to achieve exceptional growth objectives with minimal dilution crg maintains offices in boulder houston and new york for more information please visit wwwcrglpcom forwardlooking statementsthis press release contains forwardlooking statements that involve substantial risks and uncertainties all statements other than statements of historical facts contained in this press release are forwardlooking statements these statements relate to future events and involve known and unknown risks including without limitation uncertainties regarding strongbridges strategy plans future financial position anticipated investments costs and results outcomes of product development efforts status and results of clinical trials and objectives of management for future operations the words anticipate estimate expect intend may plan potential project target will would or the negative of these terms or other similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words these forwardlooking statements are based on current expectations estimates forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks uncertainties and other factors the forwardlooking statements contained in this press release are made as of the date of this press release and strongbridge biopharma does not assume any obligation to update any forwardlooking statements except as required by applicable law contacts corporate and media relations elixir health public relations lindsay rocco   lroccoelixirhealthprcom investor relations us the trout group marcy nanus   mnanustroutgroupcomeurope first house mitra hagen negård      strongbridgebiofirsthousenousa northbrook drive suite  trevose pa  tel   fax   strongbridge biopharma plc print page  rss feeds  email alerts  ir contacts you are leaving this site you are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty website closeok   strongbridge biopharma plc strongbridge biopharma ™ is a trademark of strongbridge biopharma plc keveyis ® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone  infostrongbridgebiocom comprehensive compliance program california statement of compliance strongbridge biopharma plc company profile  bloomberg feedback strongbridge biopharma plc public company company profile sector health care industry biotech  pharma subindustry biotech strongbridge biopharma plc operates as a biopharmaceutical company focused on the development inlicensing acquisition and commercialization of complementary product candidates across multiple franchises that target rare diseases the company distributes their products globally corporate information address  northbrook drive suite  trevose pa  united states phone  fax  web url wwwstrongbridgebiocom board members chairman company presidentceo company matthew pauls strongbridge biopharma plc board members company jeffrey sherman horizon pharma plc hilde steineger pronova biopharma asa garheng kong healthquest capital management co llc richard kollender rapid micro biosystems inc marten steen healthcap gp sa show more from the web press releases strongbridge biopharma plc secures  million financing from crg jul   strongbridge biopharma plc completes target enrollment of  patients in the phase  sonics study evaluating recorlev™ levok jun   strongbridge biopharma plc added to the russell ® index jun   strongbridge biopharma plc announces new employment inducement awards jun   strongbridge biopharma plc to participate in the jmp securities life science conference jun   strongbridge biopharma plc to present at the jefferies  global healthcare conference may   strongbridge biopharma plc provides corporate update and reports first quarter  financial results may   strongbridge biopharma plc announces new employment inducement awards may   key executives matthew pauls presidentceo a brian davis chief financial officer stephen j long chief legal officer fredric cohen sr vpresearch  devchief medical ofcr robert lutz chief business officer sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data strongbridge biopharma plc  sbbp  stock price today  zacks free gift for zackscom visitors sbbp is up  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more strongbridge biopharma plc sbbp delayed data from nsdq  usd     updated jul    pm et aftermarket     am et add to portfolio zacks rank buy          style scores f value  b growth  d momentum  d vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date bmo prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics bmo  before market open amc  after market close zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for sbbp all zacks’ analyst reports news for sbbp zacks news for sbbp other news for sbbp strongbridge sbbp shows strength stock moves up  am est zacks forget gilead buy these smallcap biotech stocks instead pm est zacks sbbp what are zacks experts saying now zacks private portfolio services can the uptrend continue for strongbridge biopharma sbbp am est zacks strongbridge biopharma sbbp jumps stock moves up  am est zacks more zacks news for sbbp healthcare  top  gainers  losers as of  am am est seeking alpha strongbridge biopharma plc secures  million financing from crg am est globenewswire healthcare  top  gainers  losers as of  am am est seeking alpha strongbridge biopharma plc completes target enrollment of  patients in the phase  sonics study evaluating recorlev¿ levoketoconazole in endogenous cushing¿s syndrome am est globenewswire strongbridge biopharma plc added to the russell ® index am est globenewswire more other news for sbbp premium research for sbbp zacks rank buy  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  b growth  d momentum  d vgm earnings esp  research report for sbbp snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank strongbridge biopharma plc sbbp bioverativ inc bivv cellectis sa clls enzo biochem inc enz exelixis inc exel vertex pharmaceuticals incorporated vrtx aveo pharmaceuticals inc aveo see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary strongbridge biopharma plc is a biopharmaceutical company which develops acquires and commercializes product candidates that target rare diseases its product candidate consists of cor is a cortisol inhibitor for the treatment of endogenous cushings syndrome cor and cor to treat acromegaly bp the treatment of diabetes which are in different clinical trial strongbridge biopharma plc is based in trevose pennsylvania strongbridge biopharma plc provides update on corporate progress  strongbridge biopharma plc – ir site skip to main navigation investors back strongbridge biopharma plc provides update on corporate progress releasecafcebdecbfdbcpdf  kb strongbridge prioritizes rare endocrine disease portfolio focus on cor and cor strongbridge provides update on cash position – existing cash sufficient to fund planned operations beyond receipt of data from cor phase  sonics trial dublin ireland and trevose pa march   globe newswire  strongbridge biopharma plc nasdaqsbbp a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options today announced an update on corporate progress “we believe that our rare endocrine disease assets cor and cor have the potential to be innovative new treatment options for cushing’s syndrome and acromegaly respectively where there is considerable unmet need we look forward to reaching critical nearterm development milestones for each asset including the reporting of topline data from the cor sonics trial during the first half of  and finalizing the technology to be utilized for a longacting formulation of cor later this year as part of our portfolio prioritization efforts we have decided to initiate the return of cor to antisense therapeutics we also continue to evaluate opportunities to maximize strongbridge’s growth potential and believe that the company’s current cash resources are sufficient to fund planned operations into the fourth quarter of ” said matthew pauls president and chief executive officer of strongbridge biopharma strongbridge prioritizes rare endocrine disease portfolio focus on cor and corstrongbridge has prioritized its rare endocrine disease portfolio and will continue to advance clinical development of cor levoketoconazole the company’s lead product candidate which is a cortisol inhibitor currently being studied in the global phase  sonics trial for the treatment of endogenous cushings syndrome the company will also continue to advance development of cor a nextgeneration somatostatin analog ssa with a unique receptor binding profile being investigated for the treatment of acromegaly with potential additional applications in cushings disease and neuroendocrine tumors sonics clinical trial enrollment continues to progress as planned and the company expects to report topline data during the first half of  for additional information about the sonics trial visit httpcushingssyndromestudycom the company expects to select and finalize the technology to be utilized for a proprietary longacting formulation of cor in  additional cor development activities will be sequenced to ensure that the company’s existing cash resources are sufficient to fund planned operations through the receipt of data from the cor sonics trial both cor and cor have received orphan designation from the us food and drug administration and the european medicines agency as part of strongbridge’s prioritization of its rare endocrine disease portfolio and following receipt of feedback from regulatory authorities on cor the company has initiated the return of cor a secondgeneration antisense compound for the potential treatment of acromegaly to antisense therapeutics following the return of cor all rights to develop and commercialize cor will revert to and be the responsibility of antisense therapeutics further given strongbridge’s core strategic focus on the development and commercialization of novel therapeutic options for the treatment of rare diseases the company has decided not to invest further in the development of bp a genemodified probiotic in preclinical development for the potential treatment of type  and  diabetes the company is currently exploring potential partnership and outlicensing opportunities for bp strongbridge provides update on cash position – existing cash sufficient to fund planned operations beyond receipt of data from cor phase  sonics trialas of december   strongbridge had cash and cash equivalents of  million and no outstanding debt the company believes it has sufficient existing cash and cash equivalents to fund planned operations into the fourth quarter of  which is after the expected receipt of data from the cor sonics trial strongbridge is scheduled to present a corporate overview at the cowen and company th annual health care conference on tuesday march   at  am est in boston ma the company’s presentation will be webcast live and available on the “events  presentations” page in the investor section of the company’s website at wwwstrongbridgebiocom about strongbridge biopharma strongbridge biopharma is a global rare disease biopharmaceutical company focused on the development and commercialization of novel therapeutic options strongbridge’s lead product candidate cor levoketoconazole is a cortisol inhibitor currently being studied in the global phase  sonics trial for the treatment of endogenous cushings syndrome strongbridge’s rare endocrine disease franchise also includes cor a nextgeneration somatostatin analog ssa being investigated for the treatment of acromegaly with potential additional applications in cushings disease and neuroendocrine tumors both cor and cor have received orphan designation from the us food and drug administration and the european medicines agency for more information visit wwwstrongbridgebiocom forwardlooking statementsthis press release contains forwardlooking statements that involve substantial risks and uncertainties all statements other than statements of historical facts contained in this press release are forwardlooking statements these statements relate to future events and involve known and unknown risks including without limitation uncertainties regarding strongbridges strategy plans future financial position timing of clinical study results outcomes of product development efforts and objectives of management for future operations the words anticipate estimate expect intend may plan potential project target will would or the negative of these terms or other similar expressions are intended to identify forwardlooking statements although not all forwardlooking statements contain these identifying words these forwardlooking statements are based on current expectations estimates forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks uncertainties and other factors the forwardlooking statements contained in this press release are made as of the date of this press release and strongbridge biopharma does not assume any obligation to update any forwardlooking statements except as required by applicable law contacts corporate and media relations elixir health public relations lindsay m rocco   lroccoelixirhealthprcom investor relations icr incstephanie carrington   stephaniecarringtonicrinccom usa northbrook drive suite  trevose pa  tel   fax   strongbridge biopharma plc print page  rss feeds  email alerts  ir contacts you are leaving this site you are about to leave strongbridgebiocom the link will take you to a website that may be maintained by a third party which is solely responsible for its content strongbridge provides this link as a service to its web visitors and is not responsible for the privacy policy or terms of use of any thirdparty website closeok   strongbridge biopharma plc strongbridge biopharma ™ is a trademark of strongbridge biopharma plc keveyis ® is a registered trademark licensed exclusively in the us to strongbridge biopharma plc mlr v   northbrook drive suite  trevose pa  united states phone  infostrongbridgebiocom comprehensive compliance program california statement of compliance